| CATS | Canadian American Ticlopidine Study |
|---|---|
| SNP | school nurse practitioner; sinus node potential; sodium nitroprusside |
| DRG | Dorsal Root Ganglia |
| DRG | diagnosis-related group; Division of Research Grants [NIH}; dorsal respiratory group; dorsal root ga... |
| drg | drainage |
| SNP | Single Nucleotide Polymorphism |
|---|---|
| SNP | Sodium Nitroprusside |
| AN-DRG | Australian National Diagnosis Related Group |
| DRG | Diagnosis Related Group |
| DRG | Diagnostic Related Group |
| ticlopidine | <chemical> 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine. Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis. Pharmacological action: fibrinolytic agent, platelet aggregation inhibitors. Chemical name: Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro- (12 Dec 1998) |
|---|---|
| DRG | <abbreviation> Diagnosis-related group. (05 Mar 2000) |
| outliers, drg | In health care reimbursement, especially in the prospective payment system, those patients who require an unusually long hospital stay or whose stay generates unusually high costs. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
신풍티클로피딘정 - 새창
|
신풍제약 |
A00304711 | Ticlopidine HCl | 전문의약품 | 급여 |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|